UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 14, 2004

GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

0-19635     33-0326866
(Commission File Number)     (IRS Employer Identification No.)
   
Two Connell Drive
Berkeley Heights, NJ 07922
    07922
(Address of Principal Executive Offices)     (Zip Code)


(908) 286-9800
(Registrant’s Telephone Number, Including Area Code)


(Former Name or Former Address, if Changed Since Last Report)




 


 

Item 5. Other Events and Regulation FD Disclosure.

     On May 13, 2004, Genta Incorporated (“Genta”) issued a press release announcing the withdrawal of Genta’s New Drug Application for Genasense™ in Melanoma. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Exhibit
Number
  Description

 
99.1   Press Release dated May 13, 2004

 


 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    GENTA INCORPORATED
     

Date:  May 14, 2004 By:    /s/ William P. Keane
 
 
      Name:   
William P. Keane
      Title:  Vice President, Chief Financial Officer and Corporate Secretary

 


 

EXHIBIT INDEX

Exhibit
Number
  Description Sequentially
Numbered Page
       
99.1   Press Release dated May 13, 2004